Evidence map›Paper›PMID 37391713›Full record

ArticleBMC nephrology2023

Comparison of two ferritin assay platforms to assess their level of agreement in measuring serum and plasma ferritin levels in patients with chronic kidney disease.

Sandawana William Majoni, Jane Nelson, Jessica Graham, Asanga Abeyaratne, David Kiran Fernandes, Sajiv Cherian, Geetha Rathnayake, Jenna Ashford, Lynn Hocking, Heather Cain and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC nephrology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Observational
  2. Altered iron metabolism and iron therapy in restless legs syndrome.Journal of neural transmission (Vienna, Austria : 1996) · 2026
    Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Sandawana William MajoniMenzies School of Health Research, Charles Darwin University, Northern Territory, Darwin, Australia. sandawanaw@aol.com.
Jane NelsonMenzies School of Health Research, Charles Darwin University, Northern Territory, Darwin, Australia.
Jessica GrahamMenzies School of Health Research, Charles Darwin University, Northern Territory, Darwin, Australia.
Asanga AbeyaratneMenzies School of Health Research, Charles Darwin University, Northern Territory, Darwin, Australia.
David Kiran FernandesDepartment of Nephrology, Alice Springs Hospital, Alice Springs, Northern Territory, Australia.
Sajiv CherianMenzies School of Health Research, Charles Darwin University, Northern Territory, Darwin, Australia.
Geetha RathnayakeTerritory Pathology, Darwin Northern Territory, Darwin, Australia.
Jenna AshfordTerritory Pathology, Darwin Northern Territory, Darwin, Australia.
Lynn HockingTerritory Pathology, Alice Springs, Northern Territory, Australia.
Heather CainTerritory Pathology, Darwin Northern Territory, Darwin, Australia.
Robert McFarlaneTerritory Pathology, Darwin Northern Territory, Darwin, Australia.
Paul Damian LawtonMenzies School of Health Research, Charles Darwin University, Northern Territory, Darwin, Australia.
Federica BarziMenzies School of Health Research, Charles Darwin University, Northern Territory, Darwin, Australia.
Sean TaylorMenzies School of Health Research, Charles Darwin University, Northern Territory, Darwin, Australia.
Alan CassMenzies School of Health Research, Charles Darwin University, Northern Territory, Darwin, Australia.
Alice Springs Hospital · AUCharles Darwin University · AUMenzies School of Health Research · AUNorthern Territory Health Services · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFerritin levels are used to make decisions on therapy of iron deficiency in patients with chronic kidney disease (CKD). Hyperferritinaemia, common among patients with CKD from the Northern Territory (NT) of Australia, makes use of ferritin levels as per clinical guidelines challenging. No gold standard assay exists for measuring ferritin levels. Significant variability between results from different assays creates challenges for clinical decision-making regarding iron therapy. In the NT, different laboratories use different methods. In 2018, Territory Pathology changed the assay from Abbott ARCHITECT i1000 (AA) to Ortho-Clinical Diagnostics Vitros 7600 (OCD). This was during the planning of the INtravenous iron polymaltose for First Nations Australian patients with high FERRitin levels on haemodialysis (INFERR) clinical trial. The trial design was based on AA assay ferritin levels. We compared the two assays' level of agreement in measuring ferritin levels in CKD patients.

methodsSamples from INFERR clinical trial participants were analysed. Other samples from patients whose testing were completed the same day on OCD analyzers and run within 24 h on AA analyzers were added to ensure wide range of ferritin levels, adding statistical strength to the comparison. Ferritin levels from both assays were compared using Pearson's correlation, Bland-Altman, Deming and Passing-Bablok regression analyses. Differences between sample types, plasma and serum were assessed.

resultsSixty-eight and 111 (179) samples from different patients from Central Australia and Top End of Australia, respectively, were analyzed separately and in combination. The ferritin levels ranged from 3.1 µg/L to 3354 µg/L and 3 µg/L to 2170 µg/L for AA and OCD assays respectively. Using Bland-Altman, Deming and Passing-Bablok regression methods for comparison, ferritin results were consistently 36% to 44% higher with AA than OCD assays. The bias was up to 49%. AA ferritin results were the same in serum and plasma. However, OCD ferritin results were 5% higher in serum than plasma.

conclusionsWhen making clinical decisions, using ferritin results from the same assay in patients with CKD is critical. If the assay is changed, it is essential to assess agreement between results from the new and old assays. Further studies to harmonize ferritin assays are required.

Indexed as

Clinical Decision-MakingPlasmaAdministration, IntravenousFerritinsHumansNorthern TerritoryFerritins

Identifiers

PMID37391713
PMCPMC10314376
OpenAlexW4382751398

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.